Drawing for NANOBIOTIX

USPTO serial 79293376

NANOBIOTIX

Reviewed by CopyMark Law Group

Reg. 6443537Status 700Renewal
Filing date
Status date
Registration date
Aug 10, 2021
Examiner
ADEYIGA, ADETAYO JANET
Law office
TMEG LAW OFFICE 109

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with NANOBIOTIX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,046*

Plus Government fees of $1,300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

James R Menker

James R Menker Holley & Menker, PAPO Box 331937Atlantic Beach, FL 32233UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products, namely, preparations for medical use particularly for tumor diagnosis and treatment; pharmaceutical products, namely, preparations for medical use, especially for the diagnosis and treatment of tumors using radiotherapy; radioactive products, namely, substances for medical use, especially for the diagnosis and treatment of tumors using radiotherapy; health products, namely, pharmaceutical products, for the treatment of tumors; radiological contrast substances for medical use; chemical reagents for medical use; chemical preparations for medical or pharmaceutical use, namely, for the treatment of tumors; diagnostic products for medical use, namely, medicines for the treatment of tumors; drugs for medical use, namely, pharmaceutical products for use in the treatment of cancer; medicines for human medicine, namely, pharmaceutical products for the treatment of tumors; chemico-pharmaceutical products for use in treating oncological diseases and disorders; pharmaceutical products for use in treating oncological diseases and disordersACTIVE—
010Surgical and medical apparatus and instruments, namely radiotherapy apparatus especially for the diagnosis and treatment of tumors using radiotherapy; radiotherapy apparatus; testing apparatus for medical use, namely, for testing tumor characteristics; diagnostic apparatus for medical use, namely, for testing tumor characteristics; radiological apparatus for medical use; apparatus and installations for the production of X-Rays for medical useACTIVE—
042Scientific and technological services, namely, research and design services particularly in the field of nanomedicine which is nanotechnology applied to medicine; biological research; research in bacteriology; scientific research, namely, evaluations, estimates and research in scientific and technological fields provided by engineers, researchers; design and development of new products for third parties; technical project studies, namely, technical research in the field of nanomedicine; industrial analysis of manufacturing of nanomedicines and research services in the field of nanomedicine; chemical analysis; chemical research; chemistry services, namely, chemistry consultation; surveyingACTIVE—
044Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 10, 2026REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Dec 19, 2021FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Dec 1, 2021FICSFINAL DISPOSITION NOTICE SENT TO IB—
Dec 1, 2021FIMPFINAL DISPOSITION PROCESSED—
Nov 10, 2021FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 10, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 25, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 25, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 23, 2021GPNXNOTIFICATION PROCESSED BY IB—
May 5, 2021OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
May 5, 2021OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
May 5, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 20, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 19, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 19, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 19, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 22, 2020RFNTREFUSAL PROCESSED BY IB—
Nov 2, 2020RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Nov 2, 2020RFRRREFUSAL PROCESSED BY MPU—
Oct 9, 2020RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 8, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 6, 2020DOCKASSIGNED TO EXAMINER—
Sep 15, 2020MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 11, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 10, 2020REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance